Chardan Capital Issues Positive Forecast for Senti Biosciences (NASDAQ:SNTI) Stock Price

Senti Biosciences (NASDAQ:SNTI) had its price target raised by Chardan Capital from $11.00 to $12.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

SNTI has been the topic of several other reports. Wall Street Zen raised shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Senti Biosciences Stock Performance

Shares of SNTI stock opened at $1.01 on Friday. The firm’s 50-day moving average is $0.95 and its 200-day moving average is $1.22. The stock has a market cap of $31.46 million, a price-to-earnings ratio of -0.53 and a beta of 2.09. Senti Biosciences has a 52-week low of $0.77 and a 52-week high of $3.88.

Senti Biosciences (NASDAQ:SNTI) last issued its earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.22. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Sell-side analysts predict that Senti Biosciences will post -1.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SNTI. Armistice Capital LLC acquired a new position in shares of Senti Biosciences during the 2nd quarter worth approximately $1,883,000. Geode Capital Management LLC grew its position in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Senti Biosciences during the 3rd quarter worth approximately $117,000. Virtu Financial LLC acquired a new position in shares of Senti Biosciences during the 4th quarter worth approximately $46,000. Finally, Jane Street Group LLC acquired a new position in shares of Senti Biosciences during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.